Announcements Trials
Browse Landscape

Phase

Phase 3 4Phase 2 4Phase 1 3Phase 1/2 2

Status

Completed 2Withdrawn 1Active not recruiting 1

Sponsor Class

NIH 2INDUSTRY 2

Study Type

Interventional 4

Sponsor

Cancer Type

Plasma cell 4

Conditions

Multiple Myeloma 85Lymphoma, Follicular 18Recurrence 11Lymphoma, Large B-Cell, Diffuse 11Neoplasms, Plasma Cell 8Lymphoma 7Lymphoma, B-Cell, Marginal Zone 6Lymphoma, Non-Hodgkin 5Neoplasms 4Lymphoma, Mantle-Cell 4Hematologic Diseases 4Smoldering Multiple Myeloma 3Leukemia, Lymphocytic, Chronic, B-Cell 3Disease Progression 3Paraproteinemias 2Myelodysplastic Syndromes 2Disease 2Anemia 2Sezary Syndrome 1Prostatic Neoplasms 1Polycythemia Vera 1Plasmacytoma 1Neoplasm Metastasis 1Mycosis Fungoides 1Melanoma 1Lymphoproliferative Disorders 1Lymphoma, T-Cell, Cutaneous 1Limb-girdle muscular dystrophy, type 2C 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Acute 1

Interventions

pirtobrutinib 5Lenalidomide 4Rituximab 3Imatinib Mesylate 3ruxolitinib 2ponatinib 2ibrutinib 2Platelet Transfusion 2Brentuximab Vedotin 2Bortezomib 2Bendamustine Hydrochloride 211-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene 2zanubrutinib 1vosaroxin 1venetoclax 1nilotinib 1idelalisib 1bosutinib 1acalabrutinib 1Zoledronic Acid 1Vorinostat 1Vincristine 1Tretinoin 1Prednisone 1Plasma Exchange 1Granulocyte-Macrophage Colony-Stimulating Factor 1Exercise 1Doxorubicin 1Dexamethasone 1Denosumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 3 × Hematologic Diseases × Lenalidomide × Clear all
NCT05317416 2026-04-16

MagnetisMM-7

Pfizer

Phase 3 Active not recruiting
854 enrolled
Plasma cell

Hematologic Diseases, Multiple Myeloma

NCT01109004 2021-12-09

BMT CTN 0702

National Heart, Lung, and Blood Institute (NHLBI)

Phase 3 Completed
758 enrolled 21 charts
Plasma cell

Hematologic Diseases, Multiple Myeloma, Disease Progression

NCT02322320 2020-05-11

Continued, Long-Term Follow-Up and Lenalidomide Maintenance Therapy for Patients on BMT CTN 0702 Protocol (BMT CTN 07LT)

National Heart, Lung, and Blood Institute (NHLBI)

Phase 3 Completed
273 enrolled 16 charts
Plasma cell

Hematologic Diseases, Multiple Myeloma, Disease Progression

NCT02155634 2018-04-10

Continuous Lenalidomide Therapy Versus Observation Following Induction Without Lenalidomide, Pomalidomide or Thalidomide in Myeloma

Celgene

Phase 3 Withdrawn
Plasma cell

Blood Protein Disorders, Hematologic Diseases, Multiple Myeloma, Neoplasms, Paraproteinemias

Data powered by HemOnc (CC BY 4.0) Colophon âš¡